7-oxo-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate | 1355592-32-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 7-oxo-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate
• 英文别名: (7-oxo-6,8-dihydro-5H-naphthalen-2-yl) trifluoromethanesulfonate
• CAS: 1355592-32-3
• 化学式: C₁₁H₉F₃O₄S
• 分子量: 294.251
• InChiKey: BIJBOPZCKRINES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  三氟甲磺酸酐 、 7-羟基-3,4-二氢-1H-2-萘酮 在 2,6-二甲基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以86%的产率得到7-oxo-5,6,7,8-tetrahydronaphthalen-2-yl trifluoromethanesulfonate
  参考文献：
  名称：

  SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF

  摘要：

  本发明提供了公式(I)的化合物： 其中R1、R1b、R2a、R2b、R2c和R2d的值如说明书中所述，可用作HDAC6的抑制剂。本发明还提供了包含本发明化合物的药物组合物，以及使用这些组合物治疗增殖性、炎症性、感染性、神经性或心血管疾病或失调的方法。

  公开号：

  US20120015943A1

文献信息

• SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF
  申请人：Blackburn Christopher

  公开号：US20140243335A1

  公开（公告）日：2014-08-28

  This invention provides compounds of formula (I): wherein R 1 , R 1b , R 2a , R 2b , R 2c , and R 2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式（I）的化合物：其中R1、R1b、R2a、R2b、R2c和R2d的值如说明书中所述，可用作HDAC6的抑制剂。本发明还提供了包含本发明化合物的药物组合物以及使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或疾患的方法。
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Steeneck Christoph

  公开号：US20120015920A1

  公开（公告）日：2012-01-19

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• US8835441B2
  申请人：——

  公开号：US8835441B2

  公开（公告）日：2014-09-16
• [EN] SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF<br/>[FR] ACIDES HYDROXAMIQUES SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2012012322A1

  公开（公告）日：2012-01-26

  This invention provides compounds of formula (/): (Formula (I) wherein R1, R1b, R2a, R2b, R2c, and R2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Blackburn Christopher

  公开号：US20120015943A1

  公开（公告）日：2012-01-19

  This invention provides compounds of formula (I): wherein R 1 , R 1b , R 2a , R 2b , R 2c , and R 2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了公式(I)的化合物： 其中R1、R1b、R2a、R2b、R2c和R2d的值如说明书中所述，可用作HDAC6的抑制剂。本发明还提供了包含本发明化合物的药物组合物，以及使用这些组合物治疗增殖性、炎症性、感染性、神经性或心血管疾病或失调的方法。